← FDA DRUG APPROVALS

FDA ANDA · ANDA077652

LEVOFLOXACIN

Sponsor: ZYDUS LIFESCIENCES

APPLICATION
ANDA077652
TYPE
ANDA
ORIGINAL APPROVAL
2012-09-07
LATEST ACTION
2024-09-20
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

LEVOFLOXACINPrescription
LEVOFLOXACIN 750MG · TABLET · ORAL
LEVOFLOXACINPrescription
LEVOFLOXACIN 250MG · TABLET · ORAL
LEVOFLOXACINPrescription
LEVOFLOXACIN 500MG · TABLET · ORAL

Approval history

2024-09-20Labeling · Supplement 20 · standardAP
2023-06-28Labeling · Supplement 18 · standardAP
2022-04-04Manufacturing (CMC) · Supplement 19 · unknownAP
2020-05-29Labeling · Supplement 17 · standardAP
2019-05-03Labeling · Supplement 16 · standardAP
2019-04-16Labeling · Supplement 15 · standardAP
2019-04-16Labeling · Supplement 8 · standardAP
2019-04-16Labeling · Supplement 14 · standardAP
2019-04-16Labeling · Supplement 10 · standardAP
2014-09-25Labeling · Supplement 3 · standardAP
2014-09-25Labeling · Supplement 2 · standardAP
2012-09-07OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →